Table 2

Activity of anticancer drugs in the NCI-H460 and A549 orthotopic tumor models

The survival curve of each treated group was compared with that of control by the log-rank test.

DrugDose (mg/kg/day)NCI-H460A549
ScheduleMST (range), daysT/C (%)ScheduleMST (range), daysT/C (%)
Cisplatin2Days 7, 1436.0 (23–30)108NTa
4Days 7, 1432.0 (21–37)133Days 14, 21, 2848.3 (35–57)123
8Days 7, 1439.0 (35–42)162bDays 14, 21, 2853.0 (44–55)135
Control24.1 (19–42)10039.3 (33–43)100
Vinblastine1Days 7, 1427.8 (27–31)137cNT
2Days 7, 1432.0 (26–41)158cDays 14, 21, 2844.3 (41–69)113
4Days 7, 1437.0 (29–44)183cDays 14, 21, 2854.0 (31–55)137
Control20.3 (19–27)10039.3 (33–43)100
Etoposide17.5Days 7, 10, 1424.7 (21–25)109NT
35Days 7, 10, 1437.7 (33–38)166Days 14, 17, 2143.0 (37–49)115
70Days 7, 10, 1440.0 (10–44)176Days 14, 17, 2145.0 (37–76)121
Control22.7 (19–35)10037.3 (28–63)100
Cyclophosphamide50Days 7, 1421.7 (19–22)100Days 14, 21, 2836.5 (29–38)87
100Days 7, 1423.8 (18–29)109Days 14, 21, 2842.5 (39–45)101
200Days 7, 1423.3 (15–24)107Days 14, 21, 2854.0 (29–56)129
Control21.8 (19–27)10042.0 (24–88)100
Doxorubicin5Days 7, 1430.5 (25–65)151dDays 14, 21, 2848.0 (37–65)122e
10Days 7, 1432.5 (18–45)160bDays 14, 21, 2855.3 (46–66)140
Control20.3 (19–23)10039.3 (33–43)100
Paclitaxel10Days 7, 14NTDays 14, 21, 2847.3 (29–48)100
20Days 7, 1438.0 (28–45)138Days 14, 21, 2856.8 (47–57)146b
40Days 7, 1435.0 (31–37)127Days 14, 21, 2861.3 (57–70)158c
Control27.5 (22–46)10038.8 (27–50)100
Vinorelbine2.5NTDays 14, 21, 2841.3 (29–48)109
5Days 7, 1434.0 (18–48)146dDays 14, 21, 2852.3 (42–59)138
10Days 7, 1441.8 (35–80)179dDays 14, 21, 2866.0 (54–83)174c
Control23.3 (19–24)10038.0 (33–68)100
Gemcitabine100Days 7, 1423.8 (22–37)112Days 14, 21, 2838.0 (22–44)95
200Days 7, 1422.8 (20–25)127Days 14, 21, 2837.0 (32–46)93
40028.0 (19–30)138Days 14, 21, 2841.0 (18–53)103
Control20.3 (19–23)10040.0 (27–69)100
Irinotecan10Days 5–929.8 (27–31)153Days 14–1937.8 (29–39)103
20Days 5–929.7 (24–30)152Days 14–1965.0 (36–96)178
40Days 5–931.3 (29–32)161Days 14–1949.8 (35–53)136
Control19.5 (16–37)10036.5 (28–57)100
Topotecan1.25Days 5–931.0 (26–42)159bDays 14–1944.0 (40–76)106
2.5Days 5–932.0 (31–33)164Days 14–1947.0 (33–104)113
5Days 5–912.7 (12–13)65Days 14–1921.0 (20–49)136
Control19.5 (16–37)10041.5 (24–86)100
S 16020-220Days 7, 1427.3 (25–32)122Days 14, 21, 2853.0 (39–69)143
40Days 7, 1431.0 (20–34)139Days 14, 21, 2863.3 (48–98)170c
80Days 7, 1440.7 (33–41)182cDays 14, 21, 2884.0 (65–104)226d
Control22.4 (18–36)10037.1 (21–76)100
  • a NT, not tested.

  • b P ≤ 0.05.

  • c P ≤ 0.01.

  • d P ≤ 0.001.

  • e In this experiment, doxorubicin was administered at 4 and 8 mg/kg.